Antigenics’ Oncophage Cancer Vaccine Enters Phase II Glioma Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Brain cancer trial co-sponsored by NCI follows Phase I/II investigator-sponsored study in which a tumor-specific immune response was detected in all 12 patients.
You may also be interested in...
Antigenics’ Oncophage Approved In Russia, First Therapeutic Cancer Vaccine To Enter Marketplace
The biologic will launch this summer at a price in the lower range of $50,000-$100,000/patient/year, the typical cost of new cancer drugs in Russia, firm tells “The Pink Sheet” DAILY.
Antigenics’ Oncophage Approved In Russia, First Therapeutic Cancer Vaccine To Enter Marketplace
The biologic will launch this summer at a price in the lower range of $50,000-$100,000/patient/year, the typical cost of new cancer drugs in Russia, firm tells “The Pink Sheet” DAILY.
Cell Genesys Set To License Phase III Cancer Immunotherapeutic; Final Data Likely In 2009
Interim data monitoring committee analysis raised no flags on the first of two trials of GVAX therapy in prostate cancer, CEO Sherwin reports.